ProShares Ultra Health Care (RXL) Valuation
RXL valuation today
Holdings combined · company data as of Oct 26, 2026- P/E (TTM)
- 37.6 trailing earnings
- Forward P/E
- 17.4 analyst estimates
- Price / sales
- 1.72
- Price / book
- 5.17
- EV / EBITDA
- 16.9
- Earnings yield
- 2.66% inverse of P/E
- Dividend yield
- 1.52% of the holdings
- Return on equity
- 13.7% combined
- Net margin
- 4.6% combined
- Beta
- 0.54 weighted, vs S&P 500
RXL valuation vs other stock ETFs
| ETF | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE | Net margin | Loss-makers |
|---|---|---|---|---|---|---|---|---|
| RXL | 37.6 | 17.4 | 1.72 | 5.17 | 1.52% | 13.7% | 4.6% | 5.6% |
| SPY | 25.9 | 19.9 | 3.67 | 5.47 | 1.08% | 21.1% | 14.2% | 1.9% |
| QQQ | 34.2 | 23.4 | 5.93 | 9.27 | 0.58% | 27.1% | 17.4% | 6.9% |
| DIA | 20.9 | 18.4 | 3.16 | 5.52 | 1.55% | 26.4% | 15.1% | 0.0% |
| VTI | 28.2 | 19.4 | 3.31 | 5.00 | 1.07% | 17.7% | 11.8% | 4.6% |
| IWM | n/m | 13.9 | 1.25 | 2.03 | 1.38% | −1.7% | −1.0% | 28.1% |
Same method for every fund. n/m = not meaningful (combined trailing earnings below zero or close to it). Loss-makers = weight of holdings with negative trailing earnings.
RXL valuation by sector
| Sector | Weight | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE |
|---|---|---|---|---|---|---|---|
| Healthcare | 63.0% | 37.6 | 17.4 | 1.72 | 5.17 | 1.52% | 13.7% |
RXL earnings yield vs bond yields
Earnings yield = earnings ÷ price (1 ÷ P/E). The gap to bond yields is a rough gauge of the extra return stocks are priced to deliver.
How RXL weight splits by P/E
Share of the covered weight in companies with a trailing P/E in each range.
RXL largest holdings: valuation
| Symbol | Company | Weight | P/E | Fwd P/E | P/S | Div. yield | Share of earnings |
|---|---|---|---|---|---|---|---|
| IQMM | Proshares Genius Money Market ETF | 13.47% | — | — | — | — | — |
| LLY | Eli Lilly and Company | 9.95% | 42.2 | 24.4 | 14.1 | 0.55% | 14.08% |
| JNJ | Johnson & Johnson | 6.05% | 38.8 | 21.0 | 6.2 | 2.10% | 9.32% |
| ABBV | AbbVie Inc. | 4.90% | 80.6 | 16.4 | 7.8 | 2.42% | 3.63% |
| UNH | UnitedHealth Group Incorporated | 3.71% | 25.8 | 16.6 | 0.8 | 2.31% | 8.59% |
| MRK | Merck & Co., Inc. | 3.36% | 115.8 | 15.3 | 5.4 | 2.33% | 1.73% |
| TMO | Thermo Fisher Scientific Inc. | 2.37% | 37.1 | 24.2 | 5.5 | 0.27% | 3.81% |
| AMGN | Amgen Inc. | 2.24% | 26.9 | 16.7 | 6.1 | 2.33% | 4.97% |
| GILD | Gilead Sciences, Inc. | 1.90% | — | 15.6 | 6.4 | 2.10% | −1.92% |
| ABT | Abbott Laboratories | 1.76% | 33.8 | 17.1 | 3.9 | 2.40% | 3.11% |
| PFE | Pfizer Inc. | 1.74% | 38.9 | 9.7 | 2.6 | 5.81% | 2.68% |
| ISRG | Intuitive Surgical, Inc. | 1.49% | 48.9 | 33.3 | 13.7 | — | 1.82% |
| DHR | Danaher Corporation | 1.37% | 40.8 | 23.8 | 6.4 | 0.70% | 2.01% |
| VRTX | Vertex Pharmaceuticals Incorporated | 1.26% | 28.9 | 24.1 | 10.1 | — | 2.61% |
| BMY | Bristol-Myers Squibb Company | 1.24% | 13.2 | 9.4 | 2.5 | 4.22% | 5.63% |
| CVS | CVS Health Corporation | 1.20% | 24.3 | 10.7 | 0.3 | 2.88% | 2.96% |
| MDT | Medtronic plc | 1.20% | 23.3 | 14.9 | 3.2 | 3.04% | 3.08% |
| MCK | McKesson Corporation | 1.12% | 26.9 | 19.7 | 0.3 | 0.37% | 2.49% |
| SYK | Stryker Corporation | 1.04% | 30.5 | 16.5 | 4.4 | 1.19% | 2.03% |
| ELV | Elevance Health Inc. | 0.89% | 19.0 | 13.7 | 0.5 | 1.61% | 2.81% |
| CI | Cigna Corporation | 0.82% | 12.5 | 8.3 | 0.3 | 2.06% | 3.90% |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.79% | 19.6 | 14.5 | 5.2 | 0.48% | 2.43% |
| MRNA | Moderna, Inc. | 0.76% | — | 23.0 | 39.1 | — | −1.66% |
| BSX | Boston Scientific Corporation | 0.65% | 18.0 | 13.2 | 3.1 | — | 2.17% |
| HCA | HCA Healthcare, Inc. | 0.64% | 15.4 | 13.9 | 1.3 | 0.68% | 2.48% |
Share of earnings = the holding's part of the fund's combined trailing profit. Green: earns more than its weight; orange: less. Symbol links go to each company's key metrics.
About RXL valuation
Adding up its 60 holdings with company data, RXL trades at 37.6 times trailing earnings and 17.4 times analysts' forward estimates, with a price-to-book ratio of 5.17 and a dividend yield of 1.52%. Its earnings yield of 2.66% is 2.67 percentage points below the 5.33% yield to maturity of the U.S. bond market (AGG).
The ten largest holdings are 49.7% of the fund and earn 50.0% of its combined profit. Companies that lost money over the past year are 5.6% of the covered weight.
How these figures are calculated. Each ratio treats the fund as one company: the earnings, sales and book value of every holding are added up in proportion to its weight and divided into the fund's price. In practice that is a weighted harmonic mean, so a single stock with a very high P/E cannot distort the result, and loss-making companies reduce the fund's earnings instead of being dropped. Covers 82.4% of the fund's weight (U.S.-listed stocks with company data); company figures as of October 26, 2026.
Related: RXL chart, RXL performance, RXL holdings, RXL dividends.
RXL valuation FAQ
What is the P/E ratio of RXL?
Based on its holdings, RXL has a trailing P/E of 37.6 and a forward P/E of 17.4 (earnings of all covered holdings combined in proportion to their weights, as of October 26, 2026).
What is the earnings yield of RXL?
The trailing earnings yield is 2.66% (1 ÷ P/E) and the forward earnings yield 5.75%. For comparison the U.S. bond market (AGG) yields 5.33% to maturity and T-bills about 3.91%.
Is RXL more expensive than the S&P 500?
RXL trades at 37.6 times trailing earnings versus 25.9 for the S&P 500 (SPY); on forward estimates the figures are 17.4 and 19.9.
What is the price-to-book ratio of RXL?
The holdings of RXL trade at 5.17 times book value, with a combined return on equity of 13.7%.